Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Anticancer Agents Med Chem. 2024;24(19):1407-1418. doi: 10.2174/0118715206308253240723055019.
Oncolytic Viruses (OVs) have emerged as a promising treatment option for cancer thanks to their significant research potential and encouraging results. These viruses exert a profound impact on the tumor microenvironment, making them effective against various types of cancer. In contrast, the efficacy of Chimeric antigen receptor (CAR)-T cell therapy in treating solid tumors is relatively low. The combination of OVs and CAR-T cell therapy, however, is a promising area of research. OVs play a crucial role in enhancing the tumor-suppressive microenvironment, which in turn enables CAR-T cells to function efficiently in the context of solid malignancies. This review aims to provide a comprehensive analysis of the benefits and drawbacks of OV therapy and CAR-T cell therapy, with a focus on the potential of combining these two treatment approaches.
溶瘤病毒 (OVs) 因其巨大的研究潜力和令人鼓舞的结果，已成为癌症治疗的一种有前途的选择。这些病毒对肿瘤微环境产生了深远的影响，使它们对各种类型的癌症有效。相比之下，嵌合抗原受体 (CAR)-T 细胞疗法治疗实体瘤的疗效相对较低。然而，OV 和 CAR-T 细胞疗法的联合是一个有前途的研究领域。OV 在增强肿瘤抑制性微环境方面发挥着关键作用，这反过来使 CAR-T 细胞能够在实体恶性肿瘤的背景下有效地发挥作用。本综述旨在全面分析 OV 治疗和 CAR-T 细胞治疗的优缺点，并重点探讨将这两种治疗方法结合的潜力。
